[go: up one dir, main page]

SV2017005441A - Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson - Google Patents

Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Info

Publication number
SV2017005441A
SV2017005441A SV2017005441A SV2017005441A SV2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A
Authority
SV
El Salvador
Prior art keywords
parkinson
antagonist
disease
low dose
adhd treatment
Prior art date
Application number
SV2017005441A
Other languages
English (en)
Inventor
Lone Frydelund Larsen
Johan Areberg
Nathalie Breysee
Gamini Chandrasena
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2017005441A publication Critical patent/SV2017005441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DOSIS ESPECÍFICAS DE UN ANTAGONISTA DE A2A PARA UTILIZARLO COMO UN MEDICAMENTO Y, EN PARTICULAR, QUE SEAN ÚTILES PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON Y DEL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD
SV2017005441A 2014-12-03 2017-05-12 Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson SV2017005441A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
SV2017005441A true SV2017005441A (es) 2017-08-25

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005441A SV2017005441A (es) 2014-12-03 2017-05-12 Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (es)
EP (1) EP3226863A1 (es)
JP (1) JP2017536400A (es)
KR (1) KR20170090430A (es)
CN (1) CN106999480A (es)
AU (1) AU2015357197A1 (es)
BR (1) BR112017011777A2 (es)
CA (1) CA2966582A1 (es)
CL (1) CL2017001407A1 (es)
CO (1) CO2017004785A2 (es)
CR (1) CR20170221A (es)
DO (1) DOP2017000121A (es)
EA (1) EA201790973A1 (es)
EC (1) ECSP17030050A (es)
IL (1) IL252355A0 (es)
MA (1) MA41090A (es)
MX (1) MX2017007027A (es)
NI (1) NI201700066A (es)
PE (1) PE20170926A1 (es)
PH (1) PH12017500923A1 (es)
SG (1) SG11201704370XA (es)
SV (1) SV2017005441A (es)
TN (1) TN2017000174A1 (es)
TW (1) TW201632186A (es)
WO (1) WO2016087429A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629414T3 (es) * 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
BRPI0916203A2 (pt) * 2008-07-23 2018-05-15 Kyowa Hakko Kirin Co Ltd agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
CO2017004785A2 (es) 2017-08-31
BR112017011777A2 (pt) 2018-02-20
EP3226863A1 (en) 2017-10-11
CN106999480A (zh) 2017-08-01
US20160158211A1 (en) 2016-06-09
PE20170926A1 (es) 2017-07-13
NI201700066A (es) 2018-01-04
TN2017000174A1 (en) 2018-10-19
CR20170221A (es) 2017-10-05
IL252355A0 (en) 2017-07-31
MX2017007027A (es) 2017-08-24
MA41090A (fr) 2017-10-10
DOP2017000121A (es) 2017-07-15
US20180125835A1 (en) 2018-05-10
WO2016087429A1 (en) 2016-06-09
SG11201704370XA (en) 2017-06-29
CA2966582A1 (en) 2016-06-09
EA201790973A1 (ru) 2017-10-31
TW201632186A (zh) 2016-09-16
KR20170090430A (ko) 2017-08-07
ECSP17030050A (es) 2017-08-31
PH12017500923A1 (en) 2017-11-20
JP2017536400A (ja) 2017-12-07
CL2017001407A1 (es) 2018-01-05
AU2015357197A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CR20160275A (es) Derivados del sulphamoylpyrrolamide y uso como medicamento para el tratamiento de la hepatitis b
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
SV2017005441A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
MX2017005064A (es) Metodos para tratar afecciones oculares.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017001461A (es) Terapia de combinacion.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
BR112017016333A2 (pt) compostos anticâncer
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX384637B (es) Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas.
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas